Triprolidine
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Triprolidine: From Allergic Rhinitis/Common Cold Symptoms to Allergic Urticaria
One-Sentence Summary
Triprolidine is a first-generation H1-antihistamine historically used for allergic rhinitis and common cold symptoms, though this evidence pack does not contain a documented original indication or formal mechanism-of-action record. The TxGNN model predicts it may be effective for Allergic Urticaria, with no registered clinical trials and 6 supporting publications, most of which describe the pharmacological class rather than triprolidine itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (triprolidine is a first-generation alkylamine H1-antihistamine, historically used for allergic rhinitis/common cold symptoms) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in this evidence pack. Based on known pharmacology, triprolidine is a first-generation propylamine (alkylamine)-class H1 receptor antagonist. Its mechanism directly targets the core pathology of urticaria — mast cell-mediated histamine release acting on H1 receptors, driving vasodilation, pruritus, and wheal formation. This is a textbook pharmacological class effect rather than a novel mechanistic hypothesis.
Triprolidine has long been used as the antihistamine component in cold/allergy combination products for allergic rhinitis and common cold symptoms. Allergic rhinitis and urticaria share the same IgE-mediated histamine-release pathway, so the mechanistic rationale for extending use to urticaria is plausible and consistent with how H1-antihistamines are used clinically as a drug class.
An important caveat: most of the literature identified for this prediction concerns acrivastine, a side-chain-reduced active metabolite/derivative of triprolidine, rather than triprolidine itself. Direct clinical efficacy data for triprolidine in urticaria is not present in this evidence pack — the one triprolidine-specific paper (PMID 14283425) examines skin response to UV radiation, not urticaria treatment. The prediction should therefore be read as class-level mechanistic support rather than drug-specific clinical proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7911009 | 1994 | RCT (acrivastine, not triprolidine) | Allergy | Double-blind, placebo-controlled crossover study showing acrivastine suppresses histamine/allergen-induced skin wheal response in pollen-allergic subjects |
| 1715267 | 1991 | Review | Drugs | Reviews acrivastine’s efficacy in chronic urticaria and allergic rhinitis; effective and well tolerated vs placebo, similar to clemastine/terfenadine |
| 8094649 | 1993 | Review | Dermatologic Clinics | Reviews new H1-antihistamines as first-line treatment for urticaria and mild angioedema, citing improved side-effect profile over older agents |
| 2568212 | 1989 | Review | Clinical Pharmacy | Reviews nonsedating H1-antihistamines including acrivastine, noting acrivastine is a metabolite of triprolidine |
| 1983393 | 1990 | Review | Drug and Therapeutics Bulletin | Brief review of three new non-sedating antihistamines |
| 14283425 | 1965 | Pharmacology study (not a urticaria efficacy trial) | British Journal of Dermatology | Examines triprolidine’s effect on skin response to UV radiation; not a urticaria treatment study |
South Africa Market Information
Triprolidine is not currently registered with SAHPRA (market status: not marketed); there are no product registrations on file in this evidence pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic case is strong and well-established (H1-antihistamine class effect on the histamine pathway underlying urticaria), but direct clinical evidence is for acrivastine, triprolidine’s derivative, rather than triprolidine itself, and no trials of any kind are currently registered. Combined with the drug’s unregistered status in South Africa, this warrants guardrails before any clinical pursuit.
To proceed, the following is needed:
- Confirmed mechanism-of-action documentation for triprolidine itself
- Direct clinical trial or observational evidence of triprolidine (not acrivastine) in urticaria
- SAHPRA registration pathway assessment, since the drug is currently not marketed in South Africa
- PI-sourced safety data, including contraindications, warnings, and drug interactions
- Confirmation of triprolidine’s original approved indication(s), which are not documented in this evidence pack
Additional Predicted Indications (Lower Priority, Same Evidence Pack)
| Disease | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|
| Cold urticaria | 99.97% | L4 | Research Question |
| Nasal cavity disease | 99.83% | L5 | Hold |
| Pharyngitis | 99.82% | L5 | Hold |
| Acute laryngopharyngitis | 99.82% | L5 | Hold |
| Recalcitrant atopic dermatitis | 99.70% | L5 | Hold |
| IgE responsiveness, atopic | 99.68% | L5 | Hold |
These remain model-prediction-only candidates with little to no supporting clinical or literature evidence and are not recommended for further action at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.